{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:21:15Z","timestamp":1790108475902,"version":"4.0.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Japan Agency for Medical Research","award":["24ck0106978h0001"],"award-info":[{"award-number":["24ck0106978h0001"]}]},{"DOI":"10.13039\/501100004721","name":"The University of Tokyo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004721","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Combination therapy with immune checkpoint inhibitors (ICIs) and cytotoxic or targeted anticancer agents has improved survival in multiple cancers but may exacerbate drug-related skin toxicities.\u00a0These toxicities share inflammatory mechanisms, and ICI-induced immune cell infiltration into the skin may increase both their incidence and severity. This review evaluated the impact of adding ICIs on skin toxicities in adult Asian patients\n                      <jats:bold>.<\/jats:bold>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed was searched for English-language clinical trials published between January 2014 and September 2025 using the keywords \u201cimmune checkpoint inhibitor\u201d and \u201cclinical study.\u201d Randomized controlled trials involving adult Asian patients treated with ICIs in combination with cytotoxic chemotherapy or molecularly targeted therapy were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 7287 identified articles, 28 met inclusion criteria. Studies assessed capecitabine-induced hand\u2013foot syndrome (HFS), multikinase inhibitor\u2013induced hand\u2013foot skin reaction (HFSR), taxane-induced alopecia, and epidermal growth factor receptor (EGFR) inhibitor-related skin toxicities. The incidence of capecitabine-related HFS (11\/13 articles) and EGFR inhibitor-related skin toxicities (1\/1 article) tended to be higher with the addition of ICIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>While ICIs have substantially improved survival outcomes, their immunomodulatory effects may amplify drug-specific dermatologic toxicities when used in combination regimens. Shared inflammatory pathways and immune cell recruitment to the skin likely underlie this interaction, underscoring the importance of anticipatory monitoring and optimized management strategies in combination therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10147-026-03044-9","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T10:33:00Z","timestamp":1776335580000},"page":"957-967","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Skin toxicity induced by chemotherapy or molecular targeted therapy combined with immune checkpoint inhibitors in Asian patients: A literature review by the Japanese Pharmacist-led Oncodermatology Study Team"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3473-8244","authenticated-orcid":false,"given":"Yohei","family":"Iimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akimitsu","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotoshi","family":"Iihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisanaga","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Komori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Tokuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuta","family":"Urakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Sumiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Yanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Kono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Ihira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teppei","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasumasa","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinobu","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichiro","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"3044_CR1","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s10120-024-01535-0","volume":"27","author":"N Boku","year":"2024","unstructured":"Boku N, Omori T, Shitara K et al (2024) Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric\/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial. Gastric Cancer 27:1287\u20131301. https:\/\/doi.org\/10.1007\/s10120-024-01535-0","journal-title":"Gastric Cancer"},{"key":"3044_CR2","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2024.913","author":"YK Kang","year":"2025","unstructured":"Kang YK, Ryu MH, Oh DY et al (2025) Nivolumab plus chemotherapy versus placebo plus chemotherapy in Korean patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastroesophageal junction cancer: subgroup analysis of a randomized, multicenter, double-blind phase 3 trial (ATTRACTION-4). Cancer Res Treat. https:\/\/doi.org\/10.4143\/crt.2024.913","journal-title":"Cancer Res Treat"},{"key":"3044_CR3","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh DY, Ya\u00f1ez P et al (2023) Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 24:1181\u20131195. https:\/\/doi.org\/10.1016\/S1470-2045(23)00515-6","journal-title":"Lancet Oncol"},{"key":"3044_CR4","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1007\/s12325-024-03069-4","volume":"42","author":"S Qin","year":"2025","unstructured":"Qin S, Bai Y, Li J et al (2025) First-line Pembrolizumab plus chemotherapy for HER2-negative advanced gastric cancer: China subgroup analysis of the randomized phase 3 KEYNOTE-859 study. Adv Ther 42:1892\u20131906. https:\/\/doi.org\/10.1007\/s12325-024-03069-4","journal-title":"Adv Ther"},{"key":"3044_CR5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.89678","volume":"17","author":"Y Iimura","year":"2025","unstructured":"Iimura Y, Kuroda S, Kaichi S et al (2025) A literature review and management approach for severe skin toxicity induced by Enfortumab Vedotin through sequential adaptation and combination with immune checkpoint inhibitors. Cureus 17:e89678. https:\/\/doi.org\/10.7759\/cureus.89678","journal-title":"Cureus"},{"key":"3044_CR6","doi-asserted-by":"publisher","DOI":"10.1200\/PO-24-00907","volume":"9","author":"L Huang","year":"2025","unstructured":"Huang L, Zhang S, Sun L et al (2025) Immune checkpoint inhibitors in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-resistant chemotherapy-na\u00efve advanced Non-Small Cell Lung Cancer: a meta-analysis based on eight randomized trials. JCO Precis Oncol 9:e2400907. https:\/\/doi.org\/10.1200\/PO-24-00907","journal-title":"JCO Precis Oncol"},{"key":"3044_CR7","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann MD, Paz-Ares L, Bernabe Caro R et al (2019) Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med 381:2020\u20132031. https:\/\/doi.org\/10.1056\/NEJMoa1910231","journal-title":"N Engl J Med"},{"key":"3044_CR8","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","volume":"22","author":"L Paz-Ares","year":"2021","unstructured":"Paz-Ares L, Ciuleanu TE, Cobo M et al (2021) First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol 22:198\u2013211. https:\/\/doi.org\/10.1016\/S1470-2045(20)30641-0","journal-title":"Lancet Oncol"},{"key":"3044_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.621591","volume":"11","author":"PV Viscuse","year":"2021","unstructured":"Viscuse PV, Marques-Piubelli ML, Heberton MM et al (2021) Case report: Enfortumab Vedotin for metastatic urothelial carcinoma: a case series on the clinical and histopathologic spectrum of adverse cutaneous reactions from fatal Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis to dermal hypersensitivity reaction. Front Oncol 11:621591. https:\/\/doi.org\/10.3389\/fonc.2021.621591","journal-title":"Front Oncol"},{"key":"3044_CR10","doi-asserted-by":"publisher","first-page":"1326715","DOI":"10.3389\/fonc.2024.1326715","volume":"14","author":"B Brower","year":"2024","unstructured":"Brower B, McCoy A, Ahmad H et al (2024) Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancer. Front Oncol 14:1326715. https:\/\/doi.org\/10.3389\/fonc.2024.1326715","journal-title":"Front Oncol"},{"key":"3044_CR11","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1007\/s10147-025-02895-y","volume":"30","author":"Iimura Y, Iihara H, Saito Y, Nomura H, Iwamoto T, Kotera M, Tsuchiya Y, Sumiya T, Kono M, Hirate D, Kurokawa T, Hayashi T, Hashimoto H, Higuchi J, Urakawa R, Saotome H, Kuroda S; Japanese Pharmacist-led Oncodermatology Study Team (J-PLOS)","year":"2025","unstructured":"Iimura Y, Iihara H, Saito Y, Nomura H, Iwamoto T, Kotera M, Tsuchiya Y, Sumiya T, Kono M, Hirate D, Kurokawa T, Hayashi T, Hashimoto H, Higuchi J, Urakawa R, Saotome H, Kuroda S; Japanese Pharmacist-led Oncodermatology Study Team (J-PLOS) (2025) Chemotherapy-related hand-foot syndrome and hand-foot skin reaction: a review of management and possible approaches for Asian patients by the Japanese pharmacist-led oncodermatology study team. Int J Clin Oncol 30:2474\u20132488. https:\/\/doi.org\/10.1007\/s10147-025-02895-y","journal-title":"Int J Clin Oncol"},{"key":"3044_CR12","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1007\/s10147-025-02868-1","volume":"30","author":"Y Iimura","year":"2025","unstructured":"Iimura Y, Iihara H, Saito Y et al (2025) Epidermal growth factor receptor inhibitor-related skin toxicities: a review of management and possible preventive and therapeutic approaches for Asian patients by the Japanese Pharmacist-led Oncodermatology Study Team. Int J Clin Oncol 30:2192\u20132207. https:\/\/doi.org\/10.1007\/s10147-025-02868-1","journal-title":"Int J Clin Oncol"},{"key":"3044_CR13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/978-3-319-53961-4_4","volume-title":"Dermatoanthropology of ethnic skin and hair","author":"EN LE Wiznia","year":"2017","unstructured":"LE Wiznia EN (2017) Differences in skin structure and function in ethnic populations. In: Vashi NA, Maibach HI (eds) Dermatoanthropology of ethnic skin and hair. Springer International Publishing, Cham, pp 35\u201348"},{"key":"3044_CR14","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1067\/mjd.2002.120790","volume":"46","author":"SC Taylor","year":"2002","unstructured":"Taylor SC (2002) Skin of color: biology, structure, function, and implications for dermatologic disease. J Am Acad Dermatol 46:S41\u2013S62. https:\/\/doi.org\/10.1067\/mjd.2002.120790","journal-title":"J Am Acad Dermatol"},{"key":"3044_CR15","first-page":"1","volume-title":"Skin of color: a practical guide to dermatologic diagnosis and treatment","author":"A Adegbenro","year":"2013","unstructured":"Adegbenro A, Taylor S (2013) Structural, physiological, functional, and cultural differences in skin of color. In: Alexis AF, Barbosa VH (eds) Skin of color: a practical guide to dermatologic diagnosis and treatment. Springer New York, New York, NY, pp 1\u201319"},{"key":"3044_CR16","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.1158\/1078-0432.CCR-15-2872","volume":"22","author":"SM Goldinger","year":"2016","unstructured":"Goldinger SM, Stieger P, Meier B et al (2016) Cytotoxic cutaneous adverse drug reactions during Anti-PD-1 therapy. Clin Cancer Res 22:4023\u20134029. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2872","journal-title":"Clin Cancer Res"},{"key":"3044_CR17","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/cup.12666","volume":"43","author":"KB Schaberg","year":"2016","unstructured":"Schaberg KB, Novoa RA, Wakelee HA et al (2016) Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy. J Cutan Pathol 43:339\u2013346. https:\/\/doi.org\/10.1111\/cup.12666","journal-title":"J Cutan Pathol"},{"key":"3044_CR18","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1016\/j.jaad.2012.12.963","volume":"69","author":"K Minkis","year":"2013","unstructured":"Minkis K, Garden BC, Wu S et al (2013) The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis. J Am Acad Dermatol 69:e121\u2013e128. https:\/\/doi.org\/10.1016\/j.jaad.2012.12.963","journal-title":"J Am Acad Dermatol"},{"key":"3044_CR19","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jaad.2014.02.035","volume":"71","author":"ME Lacouture","year":"2014","unstructured":"Lacouture ME, Wolchok JD, Yosipovitch G et al (2014) Ipilimumab in patients with cancer and the management of dermatologic adverse events. J Am Acad Dermatol 71:161\u2013169. https:\/\/doi.org\/10.1016\/j.jaad.2014.02.035","journal-title":"J Am Acad Dermatol"},{"key":"3044_CR20","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/ijd.13540","volume":"56","author":"RE Perret","year":"2017","unstructured":"Perret RE, Josselin N, Knol AC et al (2017) Histopathological aspects of cutaneous erythematous-papular eruptions induced by immune checkpoint inhibitors for the treatment of metastatic melanoma. Int J Dermatol 56:527\u2013533. https:\/\/doi.org\/10.1111\/ijd.13540","journal-title":"Int J Dermatol"},{"key":"3044_CR21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1158\/2326-6066.CIR-14-0134","volume":"3","author":"RW Joseph","year":"2015","unstructured":"Joseph RW, Cappel M, Goedjen B et al (2015) Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy. Cancer Immunol Res 3:18\u201322. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0134","journal-title":"Cancer Immunol Res"},{"key":"3044_CR22","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1001\/jamadermatol.2016.2226","volume":"152","author":"VJ Shi","year":"2016","unstructured":"Shi VJ, Rodic N, Gettinger S et al (2016) Clinical and histologic features of lichenoid mucocutaneous eruptions due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 immunotherapy. JAMA Dermatol 152:1128\u20131136. https:\/\/doi.org\/10.1001\/jamadermatol.2016.2226","journal-title":"JAMA Dermatol"},{"key":"3044_CR23","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","volume":"35","author":"JS Weber","year":"2017","unstructured":"Weber JS, Hodi FS, Wolchok JD et al (2017) Safety profile of nivolumab monotherapy: A pooled analysis of patients with advanced melanoma. J Clin Oncol 35:785\u2013792. https:\/\/doi.org\/10.1200\/JCO.2015.66.1389","journal-title":"J Clin Oncol"},{"key":"3044_CR24","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","volume":"30","author":"JS Weber","year":"2012","unstructured":"Weber JS, K\u00e4hler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with Ipilimumab. J Clin Oncol 30:2691\u20132697. https:\/\/doi.org\/10.1200\/JCO.2012.41.6750","journal-title":"J Clin Oncol"},{"key":"3044_CR25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ctrv.2017.05.003","volume":"57","author":"JC Hassel","year":"2017","unstructured":"Hassel JC, Heinzerling L, Aberle J et al (2017) Combined immune checkpoint blockade (anti-PD-1\/anti-CTLA-4): evaluation and management of adverse drug reactions. Cancer Treat Rev 57:36\u201349. https:\/\/doi.org\/10.1016\/j.ctrv.2017.05.003","journal-title":"Cancer Treat Rev"},{"key":"3044_CR26","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","volume":"22","author":"M Freeman-Keller","year":"2016","unstructured":"Freeman-Keller M, Kim Y, Cronin H et al (2016) Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 22:886\u2013894. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1136","journal-title":"Clin Cancer Res"},{"key":"3044_CR27","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","volume":"60","author":"VR Belum","year":"2016","unstructured":"Belum VR, Benhuri B, Postow MA et al (2016) Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer 60:12\u201325. https:\/\/doi.org\/10.1016\/j.ejca.2016.02.010","journal-title":"Eur J Cancer"},{"key":"3044_CR28","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","volume":"151","author":"M Sanlorenzo","year":"2015","unstructured":"Sanlorenzo M, Vujic I, Daud A et al (2015) Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol 151:1206\u20131212. https:\/\/doi.org\/10.1001\/jamadermatol.2015.1916","journal-title":"JAMA Dermatol"},{"key":"3044_CR29","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1046\/j.1365-2133.2002.04864.x","volume":"147","author":"R Van Doorn","year":"2002","unstructured":"Van Doorn R, Kirtschig G, Scheffer E et al (2002) Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 147:598\u2013601. https:\/\/doi.org\/10.1046\/j.1365-2133.2002.04864.x","journal-title":"Br J Dermatol"},{"key":"3044_CR30","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1046\/j.1365-2133.2001.04226.x","volume":"144","author":"KJ Busam","year":"2001","unstructured":"Busam KJ, Capodieci P, Motzer R et al (2001) Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 144:1169\u20131176. https:\/\/doi.org\/10.1046\/j.1365-2133.2001.04226.x","journal-title":"Br J Dermatol"},{"key":"3044_CR31","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1111\/j.1365-2133.2005.06885.x","volume":"153","author":"JC Pascual","year":"2005","unstructured":"Pascual JC, Belinch\u00f3n I, Sivera F et al (2005) Severe cutaneous toxicity following treatment with Gefitinib (ZD1839). Br J Dermatol 153:1222\u20131223","journal-title":"Br J Dermatol"},{"key":"3044_CR32","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1159\/000017862","volume":"196","author":"R Guy","year":"1998","unstructured":"Guy R, Kealey T (1998) Modelling the infundibulum in acne. Dermatology 196:32\u201337. https:\/\/doi.org\/10.1159\/000017862","journal-title":"Dermatology"},{"key":"3044_CR33","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0002-9440(10)63654-1","volume":"163","author":"F Mascia","year":"2003","unstructured":"Mascia F, Mariani V, Girolomoni G et al (2003) Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol 163:303\u2013312. https:\/\/doi.org\/10.1016\/S0002-9440(10)63654-1","journal-title":"Am J Pathol"},{"key":"3044_CR34","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1080\/1120009X.2024.2437336","volume":"37","author":"B Baby","year":"2025","unstructured":"Baby B, Sam N, Pn M et al (2025) Therapy-related hand-foot syndrome: a review. J Chemother 37:567\u2013578. https:\/\/doi.org\/10.1080\/1120009X.2024.2437336","journal-title":"J Chemother"},{"key":"3044_CR35","first-page":"19","volume":"14","author":"RB Diasio","year":"2000","unstructured":"Diasio RB (2000) Oral DPD-inhibitory fluoropyrimidine drugs. Oncology (Williston Park) 14:19\u201323","journal-title":"Oncology (Williston Park)"},{"key":"3044_CR36","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/j.1610-0387.2010.07449.x","volume":"8","author":"A Degen","year":"2010","unstructured":"Degen A, Alter M, Schenck F et al (2010) The hand-foot-syndrome associated with medical tumor therapy - classification and management. J Dtsch Dermatol Ges 8:652\u2013661. https:\/\/doi.org\/10.1111\/j.1610-0387.2010.07449.x","journal-title":"J Dtsch Dermatol Ges"},{"key":"3044_CR37","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s13577-012-0057-0","volume":"26","author":"N Yokomichi","year":"2013","unstructured":"Yokomichi N, Nagasawa T, Coler-Reilly A et al (2013) Pathogenesis of hand-foot syndrome induced by PEG-modified liposomal Doxorubicin. Hum Cell 26:8\u201318. https:\/\/doi.org\/10.1007\/s13577-012-0057-0","journal-title":"Hum Cell"},{"key":"3044_CR38","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1021\/acs.chemrestox.6b00215","volume":"29","author":"Y Lou","year":"2016","unstructured":"Lou Y, Wang Q, Zheng J et al (2016) Possible pathways of Capecitabine-induced hand-foot syndrome. Chem Res Toxicol 29:1591\u20131601. https:\/\/doi.org\/10.1021\/acs.chemrestox.6b00215","journal-title":"Chem Res Toxicol"},{"key":"3044_CR39","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1200\/JCO.23.01730","volume":"42","author":"A Santhosh","year":"2024","unstructured":"Santhosh A, Sharma A, Bakhshi S et al (2024) Topical Diclofenac for prevention of Capecitabine-associated hand-foot syndrome: a double-blind randomized controlled trial. J Clin Oncol 42:1821\u20131829. https:\/\/doi.org\/10.1200\/JCO.23.01730","journal-title":"J Clin Oncol"},{"key":"3044_CR40","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1007\/s10147-025-02857-4","volume":"30","author":"Y Iimura","year":"2025","unstructured":"Iimura Y, Baba K, Furukawa N et al (2025) A phase II study evaluating the preventive effect of topical Hydrocortisone for Capecitabine-induced hand-foot syndrome in patients with colorectal cancer receiving adjuvant chemotherapy with Capecitabine plus Oxaliplatin (T-CRACC study). Int J Clin Oncol 30:2316\u20132324. https:\/\/doi.org\/10.1007\/s10147-025-02857-4","journal-title":"Int J Clin Oncol"},{"key":"3044_CR41","doi-asserted-by":"publisher","first-page":"551","DOI":"10.5414\/CP203323","volume":"56","author":"Y Iimura","year":"2018","unstructured":"Iimura Y, Shimomura H, Yasu T et al (2018) NSAIDs may prevent EGFR-TKI-related skin rash in non-small cell lung cancer patients. Int J Clin Pharmacol Ther 56:551\u2013554. https:\/\/doi.org\/10.5414\/CP203323","journal-title":"Int J Clin Pharmacol Ther"},{"key":"3044_CR42","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1248\/bpb.b22-00404","volume":"45","author":"R Tanaka","year":"2022","unstructured":"Tanaka R, Ishikawa H, Sato J et al (2022) Prevention of acne-like eruption caused by Panitumumab treatment through oral administration of non-steroidal anti-inflammatory drugs. Biol Pharm Bull 45:1531\u20131536. https:\/\/doi.org\/10.1248\/bpb.b22-00404","journal-title":"Biol Pharm Bull"},{"key":"3044_CR43","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1093\/annonc\/mdv244","volume":"26","author":"B McLellan","year":"2015","unstructured":"McLellan B, Ciardiello F, Lacouture ME et al (2015) Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management. Ann Oncol 26:2017\u20132026. https:\/\/doi.org\/10.1093\/annonc\/mdv244","journal-title":"Ann Oncol"},{"key":"3044_CR44","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1007\/s10637-013-9977-0","volume":"31","author":"VR Belum","year":"2013","unstructured":"Belum VR, Wu S, Lacouture ME (2013) Risk of hand-foot skin reaction with the novel multikinase inhibitor Regorafenib: a meta-analysis. Invest New Drugs 31:1078\u20131086. https:\/\/doi.org\/10.1007\/s10637-013-9977-0","journal-title":"Invest New Drugs"},{"key":"3044_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17030411","volume":"17","author":"SI Gaumond","year":"2025","unstructured":"Gaumond SI, Beraja GE, Kamholtz I et al (2025) Chemotherapy-induced alopecia in ovarian cancer: incidence, mechanisms, and impact across treatment regimens. Cancers (Basel) 17:411. https:\/\/doi.org\/10.3390\/cancers17030411","journal-title":"Cancers (Basel)"},{"key":"3044_CR46","doi-asserted-by":"publisher","first-page":"5709","DOI":"10.3390\/curroncol31090423","volume":"31","author":"AM Perez","year":"2024","unstructured":"Perez AM, Haberland NI, Miteva M et al (2024) Chemotherapy-induced alopecia by Docetaxel: prevalence, treatment and prevention. Curr Oncol 31:5709\u20135721. https:\/\/doi.org\/10.3390\/curroncol31090423","journal-title":"Curr Oncol"},{"key":"3044_CR47","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1016\/j.jaad.2020.11.067","volume":"85","author":"KE Hirotsu","year":"2021","unstructured":"Hirotsu KE, Rana J, Wang JY et al (2021) Clinicopathologic characterization of Enfortumab Vedotin-associated cutaneous toxicity in patients with urothelial carcinoma. J Am Acad Dermatol 85:1610\u20131611. https:\/\/doi.org\/10.1016\/j.jaad.2020.11.067","journal-title":"J Am Acad Dermatol"},{"key":"3044_CR48","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1200\/JCO.19.02044","volume":"38","author":"J Rosenberg","year":"2020","unstructured":"Rosenberg J, Sridhar SS, Zhang J et al (2020) EV-101: a Phase I study of single-agent Enfortumab Vedotin in patients with Nectin-4-Positive solid tumors, including metastatic urothelial carcinoma. J Clin Oncol 38:1041\u20131049. https:\/\/doi.org\/10.1200\/JCO.19.02044","journal-title":"J Clin Oncol"},{"key":"3044_CR49","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jdcr.2024.12.019","volume":"57","author":"IA Egbeto","year":"2024","unstructured":"Egbeto IA, Vlachou E, Herrera DB et al (2024) Clinical and histopathological characterization of Enfortumab Vedotin-associated cutaneous toxicities: a case series. JAAD Case Rep 57:114\u2013121. https:\/\/doi.org\/10.1016\/j.jdcr.2024.12.019","journal-title":"JAAD Case Rep"},{"key":"3044_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.801199","volume":"11","author":"H Yang","year":"2022","unstructured":"Yang H, Yu X, An Z (2022) Cutaneous toxicity associated with Enfortumab Vedotin: a real-word study leveraging US food and drug administration adverse event reporting system. Front Oncol 11:801199. https:\/\/doi.org\/10.3389\/fonc.2021.801199","journal-title":"Front Oncol"},{"key":"3044_CR51","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1200\/JCO-25-00486","volume":"43","author":"K Shitara","year":"2025","unstructured":"Shitara K, Rha SY, Wyrwicz L et al (2025) Pembrolizumab plus chemotherapy versus chemotherapy as perioperative therapy in locally advanced gastric and gastroesophageal junction cancer: final analysis of the randomized, Phase III KEYNOTE-585 study. J Clin Oncol 43:3152\u20133159. https:\/\/doi.org\/10.1200\/JCO-25-00486","journal-title":"J Clin Oncol"},{"key":"3044_CR52","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1007\/s10147-025-02847-6","volume":"30","author":"H Yasui","year":"2025","unstructured":"Yasui H, Aizawa M, Yamaguchi K et al (2025) First-line Pembrolizumab plus chemotherapy for participants in Japan with gastric or gastroesophageal junction adenocarcinoma: subgroup analysis of the Phase 3 KEYNOTE-859 study. Int J Clin Oncol 30:2003\u20132011. https:\/\/doi.org\/10.1007\/s10147-025-02847-6","journal-title":"Int J Clin Oncol"},{"key":"3044_CR53","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S2468-1253(24)00156-0","volume":"9","author":"YK Kang","year":"2024","unstructured":"Kang YK, Terashima M, Kim YW et al (2024) Adjuvant Nivolumab plus chemotherapy versus placebo plus chemotherapy for Stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, Phase 3 trial. Lancet Gastroenterol Hepatol 9:705\u2013717. https:\/\/doi.org\/10.1016\/S2468-1253(24)00156-0","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3044_CR54","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/jjco\/hyac188","volume":"53","author":"H Satake","year":"2023","unstructured":"Satake H, Lee KW, Chung HC et al (2023) Pembrolizumab or Pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062. Jpn J Clin Oncol 53:221\u2013229. https:\/\/doi.org\/10.1093\/jjco\/hyac188","journal-title":"Jpn J Clin Oncol"},{"key":"3044_CR55","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/ijc.34296","volume":"152","author":"T Liu","year":"2023","unstructured":"Liu T, Bai Y, Lin X et al (2023) First-line Nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis. Int J Cancer 152:749\u2013760. https:\/\/doi.org\/10.1002\/ijc.34296","journal-title":"Int J Cancer"},{"issue":"2","key":"3044_CR56","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"YK Kang","year":"2025","unstructured":"Kang YK, Ryu MH, Oh DY et al (2025) Nivolumab plus chemotherapy versus placebo plus chemotherapy in Korean patients with HER2-Negative, untreated, unresectable advanced or recurrent gastric or gastroesophageal junction cancer: subgroup analysis of a randomized, multicenter, double-blind Phase 3 trial. Lancet Oncol 23(2):234\u2013247. https:\/\/doi.org\/10.1016\/S1470-2045(21)00692-6","journal-title":"Lancet Oncol"},{"key":"3044_CR57","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","volume":"6","author":"K Shitara","year":"2020","unstructured":"Shitara K, Van Cutsem E, Bang YJ et al (2020) Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: The KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol 6:1571\u20131580. https:\/\/doi.org\/10.1001\/jamaoncol.2020.3370","journal-title":"JAMA Oncol"},{"key":"3044_CR58","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M et al (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial. Lancet 398:27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2","journal-title":"Lancet"},{"key":"3044_CR59","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","volume":"402","author":"YY Janjigian","year":"2023","unstructured":"Janjigian YY, Kawazoe A, Bai Y et al (2023) Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet 402:2197\u20132208. https:\/\/doi.org\/10.1016\/S0140-6736(23)02033-0","journal-title":"Lancet"},{"key":"3044_CR60","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078876","volume":"385","author":"MZ Qiu","year":"2024","unstructured":"Qiu MZ, Oh DY, Kato K et al (2024) Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. BMJ 385:e078876. https:\/\/doi.org\/10.1136\/bmj-2023-078876","journal-title":"BMJ"},{"key":"3044_CR61","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","volume":"24","author":"JM Llovet","year":"2023","unstructured":"Llovet JM, Kudo M, Merle P et al (2023) Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol 24:1399\u20131410. https:\/\/doi.org\/10.1016\/S1470-2045(23)00469-2","journal-title":"Lancet Oncol"},{"key":"3044_CR62","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0140-6736(23)00922-4","volume":"402","author":"SK Pal","year":"2023","unstructured":"Pal SK, Albiges L, Tomczak P et al (2023) Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): A multicentre, randomised, open-label, phase 3 trial. Lancet 402:185\u2013195. https:\/\/doi.org\/10.1016\/S0140-6736(23)00922-4","journal-title":"Lancet"},{"key":"3044_CR63","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1111\/cas.15479","volume":"113","author":"S Nishio","year":"2022","unstructured":"Nishio S, Yonemori K, Usami T et al (2022) Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE-826. Cancer Sci 113:3877\u20133887. https:\/\/doi.org\/10.1111\/cas.15479","journal-title":"Cancer Sci"},{"key":"3044_CR64","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1093\/jjco\/hyac098","volume":"52","author":"S Saji","year":"2022","unstructured":"Saji S, Ohsumi S, Ito M et al (2022) Subgroup analysis of Japanese patients in a phase III randomized, controlled study of neoadjuvant atezolizumab or placebo, combined with nab-paclitaxel and anthracycline-based chemotherapy in early triple-negative breast cancer (IMpassion031). Jpn J Clin Oncol 52:1124\u20131133. https:\/\/doi.org\/10.1093\/jjco\/hyac098","journal-title":"Jpn J Clin Oncol"},{"key":"3044_CR65","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.annonc.2021.05.355","volume":"32","author":"LA Emens","year":"2021","unstructured":"Emens LA, Adams S, Barrios CH et al (2021) First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann Oncol 32:983\u2013993. https:\/\/doi.org\/10.1016\/j.annonc.2021.05.355","journal-title":"Ann Oncol"},{"key":"3044_CR66","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1200\/JCO-24-01283","volume":"43","author":"DP Petrylak","year":"2025","unstructured":"Petrylak DP, Ratta R, Matsubara N et al (2025) Pembrolizumab plus docetaxel versus docetaxel for previously treated metastatic castration-resistant prostate cancer: The randomized, double-blind, phase III KEYNOTE-921 trial. J Clin Oncol 43:1638\u20131649. https:\/\/doi.org\/10.1200\/JCO-24-01283","journal-title":"J Clin Oncol"},{"key":"3044_CR67","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","volume":"21","author":"P Schmid","year":"2020","unstructured":"Schmid P, Rugo HS, Adams S et al (2020) Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21:44\u201359. https:\/\/doi.org\/10.1016\/S1470-2045(19)30689-8","journal-title":"Lancet Oncol"},{"key":"3044_CR68","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes J, Cescon DW, Rugo HS et al (2020) Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396:1817\u20131828. https:\/\/doi.org\/10.1016\/S0140-6736(20)32531-9","journal-title":"Lancet"},{"key":"3044_CR69","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","volume":"20","author":"H West","year":"2019","unstructured":"West H, McCleod M, Hussein M et al (2019) Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20:924\u2013937. https:\/\/doi.org\/10.1016\/S1470-2045(19)30167-6","journal-title":"Lancet Oncol"},{"key":"3044_CR70","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.1200\/JCO.2016.71.7629","volume":"35","author":"R Govindan","year":"2017","unstructured":"Govindan R, Szczesna A, Ahn MJ et al (2017) Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancer. J Clin Oncol 35:3449\u20133457. https:\/\/doi.org\/10.1200\/JCO.2016.71.7629","journal-title":"J Clin Oncol"},{"key":"3044_CR71","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.annonc.2021.06.004","volume":"32","author":"S Sugawara","year":"2021","unstructured":"Sugawara S, Lee JS, Kang JH et al (2021) Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer. Ann Oncol 32:1137\u20131147. https:\/\/doi.org\/10.1016\/j.annonc.2021.06.004","journal-title":"Ann Oncol"},{"key":"3044_CR72","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ccell.2022.02.007","volume":"40","author":"ZX Wang","year":"2022","unstructured":"Wang ZX, Cui C, Yao J et al (2022) Toripalimab plus chemotherapy in treatment-na\u00efve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Cancer Cell 40:277-288.e3. https:\/\/doi.org\/10.1016\/j.ccell.2022.02.007","journal-title":"Cancer Cell"},{"key":"3044_CR73","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1001\/jamaoncol.2021.0366","volume":"7","author":"J Wang","year":"2021","unstructured":"Wang J, Lu S, Yu X et al (2021) Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: A phase 3 randomized clinical trial. JAMA Oncol 7:709\u2013717. https:\/\/doi.org\/10.1001\/jamaoncol.2021.0366","journal-title":"JAMA Oncol"},{"key":"3044_CR74","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S1470-2045(23)00108-0","volume":"24","author":"J Xu","year":"2023","unstructured":"Xu J, Kato K, Raymond E et al (2023) Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): A global, randomised, placebo-controlled, phase 3 study. Lancet Oncol 24:483\u2013495. https:\/\/doi.org\/10.1016\/S1470-2045(23)00108-0","journal-title":"Lancet Oncol"},{"key":"3044_CR75","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.jtho.2019.02.001","volume":"14","author":"JC Yang","year":"2019","unstructured":"Yang JC, Shepherd FA, Kim DW et al (2019) Osimertinib plus durvalumab versus osimertinib monotherapy in EGFR T790M-positive NSCLC following previous EGFR TKI therapy: CAURAL brief report. J Thorac Oncol 14:933\u2013939. https:\/\/doi.org\/10.1016\/j.jtho.2019.02.001","journal-title":"J Thorac Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03044-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03044-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03044-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T16:53:07Z","timestamp":1779727987000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03044-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":75,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["3044"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03044-9","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"9 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No approval of research ethics committees was required to accomplish the goals of this study because it is a review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Yohei Iimura received lecture fees from Taiho Pharmaceutical Co., Ltd, and Chugai Pharmaceutical Co., Ltd. Hirotoshi Iihara serves as a consultant to Astellas Pharma Co., Ltd., Daiichi Sankyo Co., Ltd., and Taiho Pharmaceutical Co., Ltd. Hirotoshi Iihara received lecture fees from Astellas Pharma Co., Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eli Lilly and Company., Gilead Sciences, Inc, Nippon Kayaku Co., Ltd., Ohara Pharmaceutical Co., Ltd., Sawai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Yakult Honsha Co., Ltd. Junichi Higuchi, Akimitsu Maeda, Kazuhiro Shimomura, Hirotoshi Iihara, Hironori Fujii, Takuya Iwamoto, Yoshitaka Saito, Hisanaga Nomura, Keiko Komori, Hidenori Tokuda, Ryuta Urakawa, Tatsuya Sumiya, Ryosuke Yanai, Mariko Kono, Masaki Ihira, Tomohiro Kurokawa, Yuya Ishii, Masanobu Uchiyama, Teppei Yamada, Yasumasa Tsuda, Yusuke Tsuchiya, Toshinobu Hayashi, and Seiichiro Kuroda have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}